AstraZeneca said on Sunday a review of safety data of people vaccinated with its COVID-29 vaccine has shown no evidence of an increased risk of blood clots.
The review, which covered more than 17 million people vaccinated in the United Kingdom and European Union, comes after the health authorities in some European countries suspended the use of its vaccine over the clotting issues, which has even led to the deaths of its citizens in some countries.
“A careful review of all available safety data of more than 17 million people vaccinated in the European Union and the UK with COVID-19 vaccine AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia, in any defined age group, gender, batch or in any particular country,” the company stated.
The Health Authorities in Denmark, Ireland, Norway, Iceland and Netherlands have suspended the use of the vaccine over clotting issues, while Austria stopped using a batch of the AstraZeneca shots last week while probing a death from coagulation disorders.
“It is most regrettable that countries have stopped vaccination on such ‘precautionary’ grounds: it risks doing real harm to the goal of vaccinating enough people to slow the spread of the virus, and to end the pandemic,” Peter English, a retired British government consultant in communicable disease control, told Reuters.